Targeting Mutant KRAS with Novel Mutant-Specific Pharmacological Inhibitors: Activity Against Myeloma and Other Lymphoid Malignant Cells and Molecular Mechanisms of Resistance

被引：0
|
作者：
Steinbrunn, Torsten [1 ,2 ,3 ,4 ]
Shirasaki, Ryosuke [1 ,3 ,4 ,5 ,6 ]
Dashevsky, Olga [1 ,3 ,4 ,6 ]
Tang, Huihui [1 ,3 ,4 ]
Yamano, Shizuka [1 ,3 ]
Mizuno, Rin [3 ,4 ,7 ]
Sugihara, Takeru [1 ,3 ,4 ]
Teoh, Phaik Ju [1 ,3 ,4 ,8 ,9 ]
Leypoldt, Lisa B. [1 ,3 ,4 ,10 ]
Kaji, Mariko [1 ]
Sorrell, Jeffrey [1 ]
Glassner, Brian J. [1 ,3 ,4 ]
Simoes, Ricardo De Matos [1 ,3 ,4 ,6 ]
Christensen, James [11 ]
Mitsiades, Constantine S. [1 ,3 ,4 ,6 ]
机构：
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[2] Univ Hosp Wuerzburg, Dept Med 2, Wurzburg, Germany
[3] Harvard Med Sch, Dept Med, Boston, MA USA
[4] Massachusetts Inst Technol MIT & Harvard, Broad Inst, Cambridge, England
[5] Teikyo Univ Hosp, Dept Med Oncol, Tokyo, Japan
[6] Harvard Med Sch, Ludwig Ctr, Boston, MA USA
[7] Dana Farber Canc Inst, Boston, MA USA
[8] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore
[9] Canc Sci Inst Singapore, Singapore, Singapore
[10] Univ Med Ctr Hamburg Eppendorf, Sect Pneumol, Dept Hematol Oncol & Bone Marrow Transplantat, Hamburg, Germany
[11] Mirati Therapeut, San Diego, CA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-182476
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 5 条
  • [1] CRISPR-Based Functional Genomics Studies Identify Mechanisms of Multiple Myeloma (MM) Cell Response to vs. Resistance Against Novel Pharmacological Mutant-Specific KRAS Inhibitors
    Steinbrunn, Torsten
    Shirasaki, Ryosuke
    Dashevsky, Olga
    Tang, Huihui
    Yamano, Shizuka
    Teoh, Phaik Ju
    Leypoldt, Lisa
    Mizuno, Rin
    Glassner, Brian
    Simoes, Ricardo de Matos
    Christensen, James
    Mitsiades, Constantine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S180 - S181
  • [2] Mutant-specific pharmacological inhibition of KRAS in multiple myeloma and functional genomics studies to identify mechanisms regulating myeloma cell response vs. resistance to KRAS inhibition
    Steinbrunn, Torsten
    Shirasaki, Ryosuke
    Dashevsky, Olga
    Tang, Huihui
    Yamano, Shizuka
    Teoh, Phaik Ju
    Leypoldt, Lisa
    Sugihara, Takeru
    Mizuno, Rin
    Kaji, Mariko
    Sorrell, Jeffrey
    Glassner, Brian
    Simoes, Ricardo de Matos
    Christensen, James
    Mitsiades, Constantine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S244 - S244
  • [3] Site-specific mutagenesis screening in KRAS G12D mutant library to uncover resistance mechanisms to KRAS G12D inhibitors
    Choi, Jeesoo
    Shin, Ju-young
    Kim, Taeyul K.
    Kim, Kiwook
    Kim, Jiyun
    Jeon, Eunhye
    Park, Juyeong
    Han, Yoon Dae
    Kim, Kyung-A
    Sim, Taebo
    Kim, Hui Kwon
    Kim, Han Sang
    CANCER LETTERS, 2024, 591
  • [4] Development of xenoimplants from germline BRCA1/2 mutant breast cancer (BC) for the identification of predictive biomarkers, mechanisms of resistance against poly(ADP-ribose) polymerase (PARP) inhibitors and evaluation of novel therapies
    Cruz, C.
    Ibrahim, Y.
    Morancho, B.
    Anton, P.
    Grueso, J.
    Cozar, P.
    Guzman, M.
    Aviles, P. M.
    Guillen, M. J.
    Galmarini, C.
    Arribas, J.
    Baselga, J.
    Balmana, J.
    Serra, V.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 82 - 82
  • [5] ISOLATION OF A MUTANT OF ESCHERICHIA-COLI DEFECTIVE IN CYTOSINE-SPECIFIC DEOXYRIBONUCLEIC ACID METHYLASE ACTIVITY AND IN PARTIAL PROTECTION OF BACTERIOPHAGE LAMBDA AGAINST RESTRICTION BY CELLS CONTAINING N-3 DRUG-RESISTANCE FACTOR
    HATTMAN, S
    SCHLAGMAN, S
    COUSENS, L
    JOURNAL OF BACTERIOLOGY, 1973, 115 (03) : 1103 - 1107
1